This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Composit R Study Infographic

Prescribing Information

In your older patients with mild renal impairment find out why JANUVIA could be a preferred option vs. an SGLT-2 inhibitor.1

Download a digital infographic of the CompoSIT-R study: A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in older patients with type 2 diabetes mellitus and mild renal impairement.1

More than 11 years of experience:2 the evidence continues to build for JANUVIA

This resource has been initiated and produced by MSD.

References:

  1. Scott R, et al. A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study. Diabetes Obes Metab. 2018;20:2876–2884. https://doi.org/10.1111/dom.13473
  2. JANUVIA Summary of Product Characteristics

For more information about JANUVIA® (sitagliptin):